KAREN MOY: Open Payments
NPI 1154768810 · DUNDALK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,915 in 126 payments from 30 companies in 2025. Trend: 2023 $1,474 · 2024 $1,715 · 2025 $2,915
Food & beverage: $2,915
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $431 |
| PFIZER INC. | 19 | $365 |
| Novo Nordisk Inc | 15 | $260 |
| Otsuka America Pharmaceutical, Inc. | 3 | $177 |
| Indivior Inc. | 7 | $162 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $141 |
| Vanda Pharmaceuticals Inc. | 4 | $120 |
| Lilly USA, LLC | 5 | $120 |
| Gilead Sciences, Inc. | 5 | $116 |
| Verona Pharma, Inc. | 6 | $108 |
Products named: AIRSUPRA, REXULTI, ELIQUIS, SUBLOCADE, BREZTRI, Kerendia, NURTEC ODT, HETLIOZ.
Industry payments across MD — which companies pay providers there.
